Research
Energy balance
Future trials of GLP-1 receptor agonists could focus on dual or triple agonist agents.
Exploring dual or triple agonist therapies may enhance treatment options for weight management in schizophrenia.
StrongSupportsmedium confidence
Future trials could focus on dual or triple agonist agents.
Why this rating
Based on the review of completed and ongoing trials.
Source
GLP-1 receptor agonists and weight loss in schizophrenia – past, present, and future
Mike Trott et al. · Current Opinion in Psychiatry · 2024
DOI 10.1097/yco.0000000000000952
reviewCited 16×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →